scholarly journals ELIGIBILITY FOR AND USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN VETERANS WITH TYPE 2 DIABETES AND CORONARY ARTERY DISEASE: PROSPECTIVE ANALYSIS FROM THE CARDIAC CATHETERIZATION LAB CLINICAL ASSESSMENT, REPORTING, AND TRACKING (CART) PROGRAM

2020 ◽  
Vol 75 (11) ◽  
pp. 231
Author(s):  
Demetria McNeal ◽  
Taufiq Salahuddin ◽  
Javier Valle ◽  
Kamal Henderson ◽  
Vanessa Richardson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Clinical Assessment ◽  
Prospective Analysis ◽  
Sodium Glucose Cotransporter ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Artery Disease

Abstract 332: Racial Differences in Prescribing of Sodium Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Among Veterans With Type 2 Diabetes and Coronary Artery Disease: Findings From the Veteran’s Administration Clinical Assessment, Reporting, and Tracking Program

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Demetria M McNeal ◽  
Pamela Peterson ◽  
Michael M Ho ◽  
David Saxon ◽  
Kamal H Henderson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Racial Differences ◽  
Clinical Assessment ◽  
Clinical Care ◽  
Logistic Regression Models ◽  
Receptor Agonists ◽  
Sodium Glucose Cotransporter ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Background: Recent trials have shown improved cardiovascular benefit associated outcomes with sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) treatment in patients (pts) with type 2 diabetes (T2D) and high cardiovascular (CV) risk. We examined the extent to which this new evidence has been applied in routine clinical care and whether race influenced differences in prescription rates between patients. Methods and results: We used data from the US Department of Veterans Affairs’ Clinical Assessment, Reporting, and Tracking (CART) Program (2015-2017 inclusive). Pts were deemed SGLT2i- or GLP-1RA-eligible based on EMPA-REG OUTCOME and LEADER trial criteria. Rates of use were examined among eligible pts by race/ethnicity in unadjusted and multivariable logistic regression models adjusted for age, insurance type, service connection, and clinical site. From 84 sites, 21,053 patients were eligible for an SGLT2i and 1,520 (7.2%) had one prescribed. Recipients of SGLT2i were younger (65.59 years vs 68.29 years) had a higher mean HbA1c (8.27% vs 8.02%) and were more likely white (86.0 % vs 82.6%). Compared to black pts, whites had higher odds of receiving the medication, OR = 1.38; 95% CI 1.05,1.85; p < 0.01. Among 11,913 Veterans eligible for an GLP-1RA, 477 (4.0%) had one prescribed. Recipients were younger (65.84 years vs 68.96 years), had a higher mean HbA1c (8.55% vs 8.09%) and were more likely white (83.6% vs 81.8%). Compared to black pts, whites had higher odds of receiving the medication, OR = 1.43; 95% CI 1.09, 1.92; p = 0.013. Representation of other racial/ethnic groups was insufficient for comparison. Conclusion: Appropriate prescription of SGLT2i or GLP-1RA was less likely among black than white US Veterans at high CV risk. Our results suggest that while overall uptake of these medications has been slow, there are substantial racial differences that exist concerning the prescribing of these medications. In view of these findings, additional research is needed to further investigate both institutional and clinical factors which may adversely affect the prescribing of SGLT2i and GLP-1RA in African American Veterans.

Sign in / Sign up

Export Citation Format

Share Document